Analyst Ratings for Climb Bio (CLYM)
CLYM Rating Summary
CLYM Price Target Summary
- Highest: $35.00 (Guggenheim)
- Lowest: $12.00 (Wedbush)
- Average: $25.29
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
=
Avg. $ Target:
$25.29 (+148.1%)
* Over Last 12-Mos
Rating Score: 10 / 10
Percentile Rank: 95%
Rating Score: 10 / 10
Percentile Rank: 95%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 10/20/2026 | Deutsche Bank | David Hoang | New Coverage | Buy (N/A) |
28.00 (N/A) |
9.73 (10.19) |
4.73% | Details |
| 8/3/2026 | RBC Capital | N/A | New Coverage | Outperform (N/A) |
23.00 (N/A) |
11.90 (10.19) |
-14.37% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
